<DOC>
	<DOCNO>NCT02752243</DOCNO>
	<brief_summary>Multi-site , non-randomized Phase I/II study involve child adult .</brief_summary>
	<brief_title>CIK-Cells Relapsing Patients With Acute Leukemia Myelodysplastic Syndromes After SCT .</brief_title>
	<detailed_description>This phase I/II multicenter-study investigate feasibility safety efficacy interleukin ( IL ) -15 activate CIK cell patient acute leukemia myelodysplastic syndrome ( MDS ) show evidence relapse allogeneic stem cell transplantation ( SCT ) . CIK cell infusion give interval 4-6 week accord dose escalation schedule patient impend relapse allogeneic SCT . In presence acute graft versus host disease ( aGvHD ) ≥ grade II , next schedule infusion administer .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<criteria>Acute leukemia MDS patient molecular relapse peripheral blood ( PB ) bone marrow ( BM ) sample obtain monitor relapse allogeneic SCT . 1 . MRD detect Ig/TCR gene rearrangement test 2. confirm mixed chimerism ( MC ) ≥ 1 % , 3. level ≥ 104 BCRABL/ABL ratio trigger CIK cell intervention Respecting MC , MC ≥ 1 % autologous signal PB sample confirm another PB BM sample within one week . Patients MC ≥ 1 % autologous signal CD33+ and/or CD34+ subpopulation PB sample confirm BM analysis within one week . Acute leukemia MDS patient MC ≥ 1 % autologous signal include signal CD33+ and/or CD34+ subpopulation BM sample . Patients without immunosuppressive agent steroid . Patients without chemo immune therapy , except patient thyrosinekinase inhibitor ( TKI ) treatment BCRABL positive leukemia . Patients &lt; grade II GvHD . Patients Karnowsky Lansky performance status ≥ 50 % . Patients and/or his/her legal representative review patient information/informed consent form question answer give write informed consent . • Acute leukemia MDS patient hematologic relapse &lt; day 120 allogeneic stem cell transplantation Patients 5 % malignant cell bone marrow analyse Patients immunosuppressive agent steroid . Patients chemo immune therapy , except patient thyrosinekinase inhibitor ( TKI ) BCRABL positive leukemia Patients ≥ grade II GvHD . Patients Karnowsky Lansky performance status &lt; 50 % . Patients and/or his/her legal representative review patient information/informed consent form question answer give write informed consent . HIVpositive patient . HBV/HCV patient . Patients prior solid organ transplantation . Patients treat investigational product within last 28 day five halflives ( whichever longer ) . Hypersensitivity component study drug Female patient childbearing potential agree use highly effective method birth control result low failure rate ( i.e . &lt; 1 % ) use consistently correctly . Male patient female partner childbearing potential agree use highly effective method birth control result low failure rate ( i.e . &lt; 1 % ) use consistently correctly . Pregnancy/Breastfeeding . Patients severe infection signs/symptoms infection within 2 week prior study start .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>acute leukemia</keyword>
	<keyword>myelodysplastic syndrome ( MDS )</keyword>
	<keyword>Stem Cell Transplantation</keyword>
</DOC>